Eczema (Atopic Dermatitis) Clinical Trials in Las Vegas
View 31 new treatments for Eczema (Atopic Dermatitis) in Las Vegas, NV, and nearby areas, such as Henderson. Every day, Power helps hundreds of eczema patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Nemolizumab for Eczema
Galderma Clinic, Henderson + 3 more
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Rocatinlimab for Eczema
Amgen Clinic, Las Vegas + 1 more
This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
MD
Study Director
Lebrikizumab for Eczema
Eli Lilly Clinic, Las Vegas + 1 more
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Rocatinlimab for Atopic Dermatitis
Amgen Clinic, Las Vegas + 2 more
This trial is testing a medication called rocatinlimab to see if it changes how well people respond to tetanus and meningococcal vaccines by measuring antibody levels.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
MD
Study Director
Rocatinlimab for Atopic Dermatitis
Amgen Clinic, Las Vegas + 3 more
This trial tests a new drug called rocatinlimab combined with common skin treatments on patients with eczema. The goal is to see if this combination works better than standard treatments alone by calming the immune system to reduce symptoms like redness and itching.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
MD
Study Director
Amlitelimab for Atopic Dermatitis (SHORE)
Sanofi Clinic, Las Vegas + 1 more
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on background topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate to severe AD aged 12 years and older on background TCS and/or TCI. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Rocatinlimab for Atopic Dermatitis/Eczema
Amgen Clinic, Las Vegas + 4 more
This trial is testing rocatinlimab to see if it is safe and can be tolerated by people with moderate-to-severe eczema. The medication works by calming the immune system to reduce skin inflammation and irritation.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
MD
Study Director
Upadacitinib for Eczema
AbbVie Clinic, Las Vegas + 1 more
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director
Nemolizumab for Prurigo Nodularis
Galderma Clinic, Henderson + 1 more
This trial is testing the safety of nemolizumab, a medication for people with prurigo nodularis. Prurigo nodularis is a skin condition that causes itchy, hard lumps. Nemolizumab aims to reduce itching and swelling by blocking certain signals in the body.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Amlitelimab for Eczema
Sanofi Clinic, Henderson + 2 more
This trial is testing amlitelimab, a medication for adults with moderate to severe atopic dermatitis who were in a previous trial. The study aims to see if the medication is safe and effective over an extended time. Amlitelimab works by calming the immune system to reduce skin inflammation.Show More
Recruiting
No Placebo Trial
Phase 2 & 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Page 1 of 2
Frequently Asked Questions
Explore related conditions